Anecortave acetate

Bibliography

• KLEIN R, KLEIN BE, LINTON KL: Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology (1992) 99(6):933-943.
   Google Scholar
• VINGERLING JR, DIELEMANS I, HOFMAN A et al.: The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology (1995) 102(2):205-210.
   PubMed Web of Science ®Google Scholar
• KLEIN R, ROWLAND ML, HARRIS MI: Racial/ethnic differences in age-related maculopathy. Third National Health and Nutrition Examination Survey. Ophthalmology (1995) 102(3):371-381. Erratum in: Ophthalmology (1995) 102(8):1126.
   PubMedGoogle Scholar
• KLEIN R, KLEIN BE, TOMANY SC, MEUER SM, HUANG GH: Ten-year incidence and progression of age-related maculopathy: the Beaver Dam eye study. Ophthalmology (2002) 109(10):1767-1779.
   PubMed Web of Science ®Google Scholar
• AGE-RELATED EYE DISEASESTUDY RESEARCH GROUP: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, β-carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. (2001) 119(10):1417-1436.
   PubMed Web of Science ®Google Scholar
• MACULAR PHOTOCOAGULATIONSTUDY GROUP: Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch. Ophthalmol. (1991) 109(9):1220-1231.
   PubMed Web of Science ®Google Scholar
• BRESSLER NM, BRESSLER SB, GRAGOUDAS ES: Clinical characteristics of choroidal neovascular membranes. Arch. Ophthalmol. (1987) 105(2):209-213.
   PubMed Web of Science ®Google Scholar
• BERKOW JW: Subretinal neovascularization in senile macular degeneration. Am. J. Ophthalmol. (1984) 97(2):143-147.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-ERFURTH U, HASAN T, GRAGOUDAS E, MICHAUD N, FLOTTE TJ, BIRNGRUBER R: Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology (1994) 101(12):1953-1961.
   PubMed Web of Science ®Google Scholar
• MOSHFEGHI DM, KAISER PK, GROSSNIKLAUS HE et al.: Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am. J. Ophthalmol. (2003) 135(3):343-350.
   PubMed Web of Science ®Google Scholar
• Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch. Ophthalmol. (1999) 117(10):1329-1345. Erratum in: Arch. Ophthalmol. (2000) 118(4):488.
   Google Scholar
• BRESSLER NM: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Am. J. Ophthalmol. (2002) 133(1):168-169.
   PubMed Web of Science ®Google Scholar
• VERTEPORFIN IN PHOTODYNAMICTHERAPY STUDY GROUP: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am. J. Ophthalmol. (2001) 131(5):541-560.
   PubMed Web of Science ®Google Scholar
• ISHIDA S, USUI T, YAMASHIRO K et al.: VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J. Exp. Med. (2003) 198(3):483-489.
   PubMed Web of Science ®Google Scholar
• CRUM R, SZABO S, FOLKMAN J: A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science (1985) 230:1375-1378.
   PubMed Web of Science ®Google Scholar
• CLARK AF, MELLON J, LI X-Y et al.: Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest. Ophthalmol. Vis. Sci. (1999) 40:2156-2162.
   Google Scholar
• McNATT LG, LANE D, CLARK AF: Angiostatic activity and metabolism of cortisol in the chorioallantoic membrane. J. Steroid Biochem. Molec. Biol. (1992) 42:687-693.
   PubMed Web of Science ®Google Scholar
• McNATT LG, WEIMER L, YANNI J, CLARK AF: Angiostatic activity of steroids in the chick embryo CAM and rabbit corneal models of neovascularization. J. Ocular Pharm. Therapeut. (1999) 15:413-423.
   PubMed Web of Science ®Google Scholar
• BEN EZRA D, GRIFFIN BW, MAFTZIR G et al.: Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest. Ophthalmol. Vis. Sci. (1997) 38:1954-1962.
   PubMedGoogle Scholar
• CEBULLA CM, JOCKOVICH ME, MURRAY TG: Anecortave acetate modulates MMP-2, MMp-9 and VEGF receptor expression in the LHβTAG mouse model of retinoblastoma. Invest. Ophthalmol. Vis. Sci. (2005) 46:E-1106 (Abstract).
   Google Scholar
• YANG R, McCOLLUM GW, BINBAMAN DP, PENN JS: The effect of anecortave acetate on VEGF message and protein levels in hypoxic Muller cells in rat OIR. Invest. Ophthalmol. Vis. Sci. (2005) 46:E-4177 (Abstract).
   Google Scholar
• BINGAMAN DP, LIU C, LANDERS RA, GU X: Local delivery of anecortave acetate inhibits laser-induced choroidal neovascularization (CNV) in the mouse. Invest. Ophthalmol. Vis. Sci. (2004) 45:E-1850 (Abstract).
   Google Scholar
• CASEY R, LI WW: Factors controlling ocular angiogenesis. Am. J. Ophthalmol. (1997) 124(4):521-529.
   PubMed Web of Science ®Google Scholar
• YANG R, McCOLLUM GW, BINBAMAN DP, PENN JS: Inhibition of VEGF-induced endothelial cell proliferation and differentiation by steroidal and non-steroidal cox inhibitors with variable cox-1/cox-2 selectivity. Invest. Ophthalmol. Vis. Sci. (2004) 45:E-1914 (Abstract).
   Google Scholar
• BLEI F, WILSON EL, MIGNATTI P, RIFKIN DB: Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J. Cell Physiol. (1993) 155:568-578.
   PubMed Web of Science ®Google Scholar
• PENN JS, RAJARATNAM VS, COLLIER RJ, CLARK AF: The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. (2001) 42(1):283-290.
   PubMed Web of Science ®Google Scholar
• D’AMICO DJ, GOLDBERG MF, HUDSON H et al.: Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology (2003) 110(12):2372-2383 (Discussion 2384-2385).
   PubMed Web of Science ®Google Scholar
• AUGUSTIN AJ, D’AMICO DJ, MIELER WF, SCHNEEBAUM C, BEASLEY C: Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. (2005) 243(1):9-12.
   PubMed Web of Science ®Google Scholar